soul study semaglutide Trial (NEJM 2025): Oral led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine New data from the SOUL
Pay in 4 interest-free payments of $7.01 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Live Spec
New data from the SOUL trial is in! Published in The New England Journal of Medicine this March, the study shows that oral semaglutide reduced major adverse cardiovascular events in patients with Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo Kidney International Ongoing #GLP1 RA Trials on #ASCVD #SELECT: Semaglutide vs Placebo in Patients With Obesity and ASCVD Without DM #SOUL: Semaglutide vs Placebo in Adults With T2D With ASCVD or CKD #SURPASS CVOT: Tirzepatide Oral Semaglutide 25 mg delivers double digit weight loss in OASIS 4 (Phase 3 trial) Just out in NEJM: A 71 week RCT tested oral semaglutide 25 mg daily in adults soul semaglutide The SOUL trial (Semaglutide Cardiovascular Outcomes Trial) was a randomized, double blind, placebo controlled cardiovascular outcomes trial that enrolled 9,650 patients aged 50 years or older with
Store: live-language.pl · Domain: live-language.pl





















